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a  b  s  t  r  a  c  t
A  system  using  energy-dispersive  X-ray  diffraction  (EDXRD)  has  been  developed  and  tested  using  mul-
tivariate  calibration  for the quantitative  analysis  of  tablet-form  mixtures  of  common  pharmaceutical
ingredients.  A  principal  advantage  of  EDXRD  over  the  more  traditional  and  common  angular  dispersive
X-ray  diffraction  technique  (ADXRD)  is the  potential  of  EDXRD  to  analyse  tablets  within  their packaging,
due  to the  higher  energy  X-rays  used.
In the  experiment,  a  series  of  caffeine,  paracetamol  and  microcrystalline  cellulose  mixtures  were  pre-
pared  and  pressed  into  tablets.  EDXRD  profiles  were  recorded  on each  sample  and  a principal  component
analysis  (PCA)  was  carried  out  in both  unpackaged  and  packaged  scenarios.  In both  cases  the  first  two
principal  components  explained  >98%  of the  between-sample  variance.  The  PCA  projected  the sample
profiles  into  two  dimensional  principal  component  space  in close  accordance  to  their  ternary  mixture
design,  demonstrating  the  discriminating  potential  of  the  EDXRD  system.
A  partial  least  squares  regression  (PLSR)  model  was  built  with  the  samples  and  was  validated  using
leave-one-out  cross-validation.  Low  prediction  errors  of between  2% and  4%  for both  unpackaged  and
packaged  tablets  were obtained  for all  three  chemical  compounds.  The  prediction  capability  through
packaging  demonstrates  a truly  non-destructive  method  for quantifying  tablet  composition  and  demon-
strates  good  potential  for EDXRD  to be  applied  in  the  field  of  counterfeit  medicine  screening  and
pharmaceutical  quality  control.
© 2018  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
EDXRD is a powerful tool for characterizing the chemical com-
position of crystalline materials. Materials which fall into this
category include powder-form illicit drugs and plastic explosives,
both of which have been studied using EDXRD [1–3]. The advan-
tages of this technique include the use of high-energy photons
which are capable of penetrating the surface of materials and char-
acterising the layers beneath. This is a highly attractive capability in
security screening contexts and for the determination of medicine
quality. In both types of context a low level of disruption is desirable
and EDXRD provides a non-destructive and non-invasive means of
testing. A recent study has demonstrated that chemically-relevant
features from EDXRD data can be observed for aspirin tablets when
they are within blister packaging [4]. A quantitative analysis of
unpackaged pharmaceutical formulations using EDXRD and mul-
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tivariate calibration methods was  carried out in a previous study
and demonstrated good capability to predict concentrations of the
constituent compounds [5]. In the present study we demonstrate
again this capability and extend it to modelling and quantifying the
chemical composition of the same samples through blister and card
packaging simultaneously.
There are many examples of Raman spectroscopy being com-
bined with multivariate calibration for quantitative analysis of
pharmaceutical mixtures [6–10]. One such study [10] looked at
ternary mixtures of paracetamol, starch and sucrose, covering a
range of concentrations. The Raman spectra were acquired through
blister packaging to construct a partial least squares (PLS) regres-
sion model, resulting in a root mean square error of cross validation
(RMSECV) of 1.4%, and the authors observed the potential appli-
cation to counterfeit medicines detection. Fraser et al. carried out
a semi-quantitative analysis of active pharmaceutical ingredients
(APIs) in intact tablets of erectile dysfunction medicines, includ-
ing counterfeit versions – the PLS calibration model in this case
was constructed from Raman spectra from tablet ‘cores’, i.e. with
https://doi.org/10.1016/j.jpba.2017.12.036
0731-7085/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. X-ray incident on two parallel planes at an angle , with photon wavelength
  and planar spacing d. The thicker ray line represents the additional path length
traversed in a reflection from the lower plane which, for a coherent scattering event,
is  an integer multiple of the X-ray wavelength, satisfying Bragg’s law.
the coating removed. Using selected bands of the spectra and pre-
processing, a RMSECV of 7.38% was achieved in the best case [9].
Several studies have combined ADXRD with PLSR on phar-
maceutical mixtures often with comparisons made to Raman
spectroscopy [11–17]. However, none of these studies analysed
formulations within any form of packaging materials.
To the authors’ knowledge, there have been no previous studies
into the non-destructive quantitative analysis of pharmaceuti-
cal mixtures through packaging using EDXRD and chemometrics,
which form the basis of this study. The following section introduces
some principles of X-ray diffraction (XRD) to explain the physical
phenomena giving rise to the features observed in the experimental
data.
1.1. X-ray diffraction
Crystalline materials – such as polycrystalline powders of
the chemicals used in pharmaceutical formulations – comprise
molecules which are arranged in an ordered three-dimensional
structure repeated throughout the crystal. Sets of parallel molecu-
lar planes arise from this long range order [18]. These sets of planes,
in particular the separation between them, are unique to the mate-
rial and thus present an opportunity for material identification. It is
through XRD that we can achieve this characterisation of materials.
X-rays of the same energy scatter coherently from molecules in
adjacent planes when constructive interference occurs. The condi-
tions to be satisfied for the detection of a coherent scattering event
are shown in Fig. 1 and are defined by Bragg’s law:
n = 2d sin , (1)
where  is the wavelength of the incident X-ray, d is the interplanar
spacing and  is the angle subtended by the X-ray source, the sample
and the detector.
There are two ways in which Bragg’s Law can be interpreted
for use in XRD experiments. Firstly, in ADXRD, monochromatic X-
rays are used (i.e. fixed ) and diffraction peaks are detected for a
range of angles. ADXRD provides high-resolution XRD profiles, but
the relatively low energy X-rays used do not pass through thick
samples. Secondly, in energy-dispersive XRD (EDXRD), the sample
is irradiated with polychromatic X-rays and an energy-resolving
detector collects a diffraction spectrum at a fixed angle. The qual-
ity of diffraction patterns is limited by the energy resolution of
the detector, and more importantly, by the loss of angular reso-
lution due to collimators allowing a range of angles, i.e. deviations
from the nominal angle, of X-rays through. This is a necessary com-
promise in order to collect an adequate number of counts in an
acceptable time scale for screening applications, but results in sig-
nificantly broader, overlapping peaks compared to ADXRD profiles.
It is common to convert the energies of an EDXRD spectrum
to units of momentum transfer x, which incorporates diffraction
dependence on scattering angles and X-ray energy. This is useful
for making comparisons between EDXRD systems, and between





sin  = E
hc
sin , (2)





where h is Planck’s constant c is the speed of light in vacuo.
The advantages of EDXRD are that the lack of moving parts
in the instrumentation can make data collection more rapid and
the higher energies of X-rays used can penetrate bulkier samples.
EDXRD can therefore be used for non-destructive analysis of mate-
rials.
It is assumed that statistically, all possible orientations – and
hence planes – of the crystals are represented equally in a pow-
der. However, some crystals have shapes that create a tendency for
them to align in a certain way, in which case some crystal planes
are over-represented in the resulting diffraction pattern – this is
the preferred orientation effect. This effect is often stated as being
a limiting factor of the use of ADXRD in the aforementioned studies.
Another relevant physical phenomenon in X-ray screening is
that of attenuation. Materials attenuate the beam and reduce the
flux of photons which are transmitted through the material. Atten-
uation is greater for lower-energy photons as well as for thicker
materials. Moreover, the molecular composition of the material
itself has its own  energy dependent attenuation profile, (E). The
percentage of X-ray photons at an energy E which will be trans-
mitted through a material of thickness x which has an attenuation
coefficient of (E) is defined by the Beer–Lambert law:
I(E) = exp(−(E)x), (4)
where I is the relative intensity of the X-ray beam at energy E fol-
lowing the interaction with the material. The effect of attenuation
by packaged tablets at lower energies is therefore appreciable.
2. Materials and methods
2.1. Sample preparation
Paracetamol (Acetaminophen BioXtra, ≥99.0%; Sigma Aldrich),
caffeine (ReagentPlus; Sigma Aldrich), and microcrystalline cel-
lulose (average particle size 50 m;  Acros Organics) were the
ingredients of the ternary mixtures and were all used as received.
The former two are common APIs, and the latter is a common
excipient used as a dilutant. Microcrystalline cellulose was an
appropriate excipient as it has an XRD spectrum that is represen-
tative of other common excipients in terms of its peak broadness
and momentum transfer range in its XRD profile.
The calibration mixture design is shown by the triangles in Fig. 2.
Such a design simplex is common to mixture analysis experiments
and has been used to enable the system to be compared to other
studies [11,13].
Each sample mixture was  ground with an agate mortar and pes-
tle for three minutes to mix  thoroughly and to reduce particle sizes
– with the aim to decrease preferred orientation effects [13]. More
vigorous mixing techniques such as milling were avoided to pre-
vent potential polymorph phase transitions [11,13,15,19]. Sieving
was also avoided as the paracetamol powder exhibited a build-up
of electrostatic charge when ground, making it difficult to handle;
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Fig. 2. Ternary mixture design of formulations used in the experiment. Filled trian-
gles  are samples used in calibration and cross-validation.
this additional step also risked introducing artefacts resulting from
selecting particles of a certain size [16,20].
400 mg  of each mixture was transferred to a 13 mm-diameter
die and pressed into tablets using an automated Speca Press. A 1-
ton load (equivalent to 67.0 MPa) was applied, with a dwell time
of two seconds before the pressure was released. The compacted
tablets were then extracted carefully from the die.
2.2. EDXRD system
A schematic of the system used in the EDXRD experiment is
shown in Fig. 3. The X-ray source was a water-cooled Comet MXR-
160 X-ray tube with tungsten target. The source was operated at a
peak voltage of 60 kV and 2 mA  current.
A high-purity germanium (HPGe) detector (model GLP-
36360/13-P, EG&G Ortec) was positioned at approximately 4 cm
from the scatter collimator to detect scattering events. The detector
was held at a temperature of 77 K and was coupled to a multi-
channel analyser to produce an energy-space histogram for each
sample. Each detected photon was assigned to one of 512 channels.
The nominal scattering angle (2) was 6.3◦ – determined by
comparing the peak positions for a caffeine sample spectrum to
those from a caffeine reference spectrum. The beam spot size was
calculated to be 1.6 mm in diameter at the sample.
2.3. Sample scanning
All samples were scanned in triplicate, with a different part or
side of the tablet scanned each time. For the “packaged” sample
scans, pieces of card, foil and plastic taken from Sainsbury’s parac-
etamol packaging were cut to size and fashioned into a sample
holder such that the tablets would have foil and card on one side,
and plastic and card on the other.
After initial scans, a preferred orientation effect was  evident
in all samples containing paracetamol, with some peaks showing
large variations in intensity between scans. Rotating the sample
was not an option in this experimental setup, nor would it be suit-
able for the ultimate goal of scanning whole tablets in packaging.
Others have overcome this issue by either shaking samples, or by
scanning at different points to smooth out discrepancies [21,22]. In
this instance, a set of translation stages was  added and used to scan
all paracetamol-containing tablets in 30 positions for 10 s per step.
All samples not containing paracetamol were scanned continuously
for 300 s.
2.4. Multivariate analysis
The two multivariate analysis methods used in this study
were principal component analysis (PCA) and partial least squares
regression (PLSR). Both methods are powerful tools in chemi-
cal mixture analysis, for X-ray diffraction data and spectroscopic
data in general. Such data have high correlation between vari-
ables within their profiles, specifically between energy channels
in this study. As such, the high dimensional spectral data have
a low-dimensional latent structure to describe the variation in
the chemistry of the mixture set. This lower dimensionality, often
referred to as chemical rank, corresponds closely to the number
of compounds comprising the mixtures. These methods transform
the data into a few mutually-orthogonal latent variables which
between them account for almost all of the variance found in the
data set, and allow us to discard uninformative data or noise.
PCA is used in this study as an exploratory tool, enabling us to
identify possible groupings or patterns of samples from transform-
ing the EDXRD data alone, and to then compare these groupings
to known reference chemistry. By doing this we get an insight into
the power of the experimental system to discriminate chemical
information of interest.
PLSR is used to build calibration models which relate the
known chemical information, such as sample concentrations, to
the instrumental response measured by our system. If we define
the concentrations of a compound as a response vector y and the
corresponding multivariate EDXRD profiles as a matrix of explana-
tory variables X, then the calibration building stage aims to form a
linear regression model between the two:
y = X  ˇ + ε, (5)
where  ˇ is the vector of regression coefficients which we estimate
as ˆˇ  using the method of partial least squares [23,24]. ε is the error
not explained by the model. PLS models the covariance between the
reference chemistry and the EDXRD profiles of the calibration data.
Typically, a small number of principal latent variables are selected
and the regression coefficients between the reference chemistry
and the instrumental response are calculated. The model is then
used with EDXRD profiles of test samples to predict their concen-
trations in order to validate the regression model. The method of
model validation used in this study is leave-one-sample-out cross-
validation. A RMSECV is calculated for the model from the average
magnitude of the residual of predicted concentration and refer-
ence concentration for all samples. It is through validation that the
appropriateness of data pre-treatment methods, the range of ener-
gies, and the number of latent variables in the PLS model can be
assessed and an optimal modelling approach determined.
2.5. Data pre-treatment
In addition to modelling the raw EDXRD data, the data have
been transformed by a range of pre-treatments using common
chemometric techniques to determine whether they improve the
performance of the PLSR model compared to using only the raw
profiles. The transformations used are standard normal variate
(SNV) and multiplicative scatter correction (MSC), which have been
shown in NIR spectroscopy to correct for multiplicative scatter-
ing and other physical effects such as particle size and in some
instances lead to model improvement. A first-order derivative pre-
treatment has also been carried out on the EDXRD data which may
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Fig. 3. Schematic of the EDXRD system.
Fig. 4. Plots (A) and (C) show the profiles in triplicate of samples 2 and 11, respectively, when translational stages were not used. Plots (B) and (D) are the corresponding
profiles  when intra-screening translational stages were introduced – preferred orientation effects caused by paracetamol were greatly reduced.
correct for potential baseline drift across profiles [25]. In order
to determine the effect on prediction accuracy of X-ray atten-
uation at low energies, both a ‘short’ and ‘long’ spectral region
were studied. The former region corresponds to 12.2–40.3 keV, or
0.538–1.78 nm−1; the latter region encompassed the full range of
the X-ray tube spectrum, i.e. 4.02–56.6 keV, or 0.178–2.50 nm−1.
2.6. Software
The plotting of EDXRD profiles was carried out using Mat-
lab (R2017b, v.9.3, Mathworks). The Unscrambler (v.9.5, CAMO,
Norway) software was used for the multivariate analysis methods
PCA and PLSR, pre-treatments and model checking diagnostics.
3. Results and discussion
3.1. Exploratory analysis
3.1.1. Unpackaged samples
Each sample was scanned in triplicate and the three profiles per
sample were averaged. Plots (A) and (C) in Fig. 4 show triplicate
measurements of two samples containing paracetamol, samples
2 and 11. Very prominent preferred orientation effects can be
observed between 0.5 and 1.0 nm−1 in momentum transfer space
between the triplicate measurements. However, when the transla-
tional stages were implemented the preferred orientation effects
of paracetamol were greatly reduced as shown plots (B) and (D) of
Fig. 4.
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Fig. 5. Plots (A) and (B) show the raw data of the samples of unpackaged tablets and the corresponding scores plots of the first two PCs for all samples from the left to right,
respectively. Plots (C) and (D) show the raw data of the samples of packaged tablets and the corresponding scores plots of the first two  PCs for all samples from the left to
right,  respectively. Pure sample profiles are also plotted separately in Supplementary Data 1.
The 22 averaged profiles for the unpackaged mixtures are plot-
ted in Fig. 5(A). An important feature of EDXRD data is heavy
overlapping of peaks which is demonstrated in the figure. No partic-
ular energy range can therefore describe the variation of a particular
chemical across the sample set, which motivates the use of multi-
variate analysis.
The Beer–Lambert equation given in (3) enables the attenua-
tion effect of compounds of specified thicknesses and densities on
particular X-ray energies to be calculated. The attenuation effect
on X-rays of caffeine, paracetamol and microcrystalline cellulose
at thicknesses of ∼0.25 cm used in this experiment only become
appreciable below ∼11 keV (0.5 nm−1 in this setup) – calculated
using tables of mass attenuation coefficients () obtained from the
NIST X-COM database [26]. The majority of the energy window for
EDXRD profiles is not therefore affected by self-attenuation effects.
A principal component analysis was carried out on mean-
centred, ‘long’, averaged profiles of the 22 samples in the training
set. Fig. 5(B) shows the scores plot for the first two  PCs, which
account for 93% and 5.6% of the explained variance across the data,
respectively. A two-dimensional principal component projection
of the EDXRD data clearly separates the sample profiles closely in
accordance with their coordinates in the mixture design of Fig. 2.
This is an encouraging result for when the aim is to regress the
EDXRD against the reference concentrations to build a regression
model.
3.1.2. Packaged samples
The 22 averaged profiles for the packaged mixtures are plot-
ted in Fig. 5(C). The aluminium and polyvinyl chloride (PVC) which
comprises blister packaging [27], plus the card material of the outer
packaging, contribute to X-ray attenuation and scattering in the
profiles. Fig. 6 demonstrates the effect of packaging for samples 4,
9 and 18 compared to unpackaged samples. Despite the attenua-
tion effect of the packaging material, the diffraction peak features
are still observed. There is a higher intensity for packaged tablets
around a momentum transfer of 1.2 nm−1 than for unpackaged
samples which can be attributed to the scattering from the pack-
aging material itself.
In the principal component analysis of the packaged samples the
between sample explained variances for the first three PCs were
90%, 8.1% and 0.74% respectively. The first two PCs have been plot-
ted in Fig. 5(D). Despite the packaging effects causing observable
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Fig. 6. The high attenuation at low energies is exemplified using several sample
profiles in and out of packaging.
Table 1
Results of PLSR: RMSECV calculated for all models and for all three compounds;
‘short’ spectrum results in italics in each case; and number of PLS-factors used in
parentheses. All data were mean-centred.
RMSECV (weight %) Raw MSC  SNV 1st derivative
Unpackaged
Caffeine 2.00 (2) 3.88 (3) 2.57 (3) 2.34 (1)
1.99 (2) 3.68 (3) 2.54 (3) 2.34 (1)
Paracetamol 2.41 (2) 4.22 (3) 3.66 (2) 2.26 (2)
2.58 (2) 4.47 (3) 3.78 (2) 2.39 (2)
Mic. cellulose 1.78 (3) 5.54 (2) 4.00 (2) 1.85 (2)
1.97 (2) 5.85 (2) 4.47 (2) 1.87 (2)
Packaged
Caffeine 2.04 (2) 1.47 (2) 1.94 (2) 1.84 (3)
2.03 (2) 1.46 (2) 1.94 (2) 1.84 (3)
Paracetamol 2.88 (3) 3.52 (2) 3.13 (3) 2.59 (3)
2.89 (3) 3.51 (2) 3.10 (3) 2.58 (3)
Mic. cellulose 2.20 (3) 2.71 (2) 2.10 (3) 2.92 (2)
2.26 (3) 2.69 (2) 2.11 (3) 2.92 (2)
distortion to the diffraction profiles, the scores from the PCA still
separate the objects in a manner comparable to the ternary design
of the mixture compositions shown in Fig. 2.
3.2. Model calibration
3.2.1. Unpackaged
PLSR was used for model calibration using the mean spectra
for the 22 samples in the training set as explanatory variables, X,
and the nominal concentrations of the mixture components as the
response variables y. The pre-treatments described in Section 2.5
were applied to the data and a separate model built for each.
The models were validated using leave-one-out cross-validation
where for each model a RMSECV was calculated. The optimum
number of PLS-factors was then chosen by selecting the number
of latent variables which minimized the error statistic with lower
numbers of latent variables favoured, when errors were compara-
ble, to avoid overfitting the data. The results are provided in Table 1.
Diagnostic tools presented in Beebe et al. [28] were used to check
for sample leverage and sample outliers for each model. No sam-
ples had high leverage and residuals simultaneously for any of the
models and therefore no samples were identified as outliers.
Fig. 7. The predicted leave-one-out cross validation results for the raw EDXRD data
of  unpackaged tablets for the three compounds.
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Fig. 8. The predicted leave-one-out cross validation results for the raw EDXRD data
of packaged tablets for the three compounds.
The application of MSC  and SNV as pre-processing methods did
not improve the model, as can be seen from the similar or higher
RMSECVs. For MSC, the diagnostic plot of spectral value versus
mean spectral value did not show any strong tendencies for dif-
ferent slopes or offsets between samples, which indicated that it
was probably not needed.
In the absence of any improvement to the model performance
from using pre-treatments, the use of raw EDXRD in a PLSR model
was deemed suitable. The predicted concentrations from cross-
validation for the raw, ‘long’ spectra are plotted against reference
concentrations in Fig. 7.
The paracetamol concentration predictions were more spread,
as expected by the variations in spectra from preferred orienta-
tion. The RMSECV values thus follow from this by showing that the
largest errors were for paracetamol; the caffeine and cellulose val-
ues exhibited smaller errors. It is important to note that the nominal
concentration values are likely to differ from the actual concentra-
tions due to errors introduced when measuring the powders and
due to possible inhomogeneity in the mixture; in a similar experi-
ment by Moore et al., the cumulative error in preparing such tablets
was estimated to be 2–3% [16].
These results are therefore encouraging – in fact, the RMSECV
values were better than those quoted in the literature for quantita-
tion of ternary mixtures by ADXRD, and on a par with results from
Raman spectroscopy [15].
3.2.2. Packaged
The same modelling used for unpackaged tablets was  applied to
packaged tablets.
RMSECVs for the PLSR model based on raw, ‘long’ spectra were
in general higher than for the unpackaged case. There was  a 20% and
24% increase on the RMSECV values for paracetamol and microcrys-
talline cellulose respectively, but only a 2% increase for caffeine. It
is possible that some of the potential change in prediction error
for caffeine has been mitigated by the greater effect of attenuation
on its first peak, with lower peak amplitudes having smaller errors
according to Poisson counting statistics [29].
The results from the modelling of packaged tablets are com-
parable to those of unpackaged tablets and within the range of
uncertainty of the reference chemistry according to Moore et al.
[16]. As with the unpackaged models, modelling of the raw EDXRD
data was found to be as good or better than when using data
pre-treatments and no sample outliers were observed from model
diagnostic tests for any model. The predicted concentrations from
cross-validation for the raw, ‘long’ spectra were plotted against
reference concentrations in Fig. 8.
4. Conclusions
A preliminary study using energy dispersive X-ray diffraction
to predict the concentration of common ingredients in pharma-
ceutical tablets has been carried out. An EDXRD system has been
developed and multivariate calibration has been used to model
the EDXRD profiles when the tablets are unpackaged and pack-
aged. This study shows similar accuracy is obtained for both the
unpackaged and packaged scenarios for the mixtures.
One disadvantage of calibration methods for composition res-
olution is that they cannot model or account for all possible
adulterants or interferents which may  be encountered during
screening. Future work will therefore explore soft modelling meth-
ods to characterise the chemistry of samples which are more robust
to interferents.
A further limitation to the study is that only three pharmaceu-
tical compounds have been analysed and the formulations were
prepared in the laboratory for the purposes of the study. Fur-
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ther work is required to determine the capability of predicting
the concentrations of industrially manufactured medicines using
the method described. Furthermore, the current trend to include
amorphous compounds in pharmaceutical formulations motivates
the evaluation of the method using less crystalline compounds.
However, a recent study by Moss et al. [30] has demonstrated the
potential of EDXRD to discriminate amorphous materials in breast
tissue such as tumour and fatty tissue.
Limitations notwithstanding, the analysis here shows that high
accuracy can be achieved using EDXRD to characterise pharma-
ceutical formulations and the technology could be put to effective
use for truly non-destructive counterfeit medicine screening and
pharmaceutical quality control.
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